Why Mounjaro may not seem to be working for weight loss — and what the evidence says

Is it too early to judge whether Mounjaro is working?

This is the question worth asking first. The first pen (four weeks at 2.5 mg) is a settling-in dose. Its job is to reduce the chance of nausea and vomiting when you start, not to suppress appetite to a clinically meaningful degree. Many people feel almost nothing during this phase and conclude the medicine isn't for them. That conclusion is almost always premature.

Dose titration typically follows in four-week steps: 2.5 mg, then 5 mg, then higher if tolerated and clinically appropriate. Appetite suppression tends to strengthen with each increase. The timeline for Mounjaro to produce noticeable weight loss varies considerably between individuals, but weeks six to twelve (once you're at 5 mg or above) is when most people report the appetite change becoming real.

SURMOUNT-1, the pivotal trial published in the New England Journal of Medicine, followed 2,539 adults over 72 weeks. Average body-weight reduction at the highest dose was around 20–21%. That happened across more than a year of gradual titration and lifestyle adjustment, not in a month. If you're at week three wondering why the scales haven't moved, the honest answer is: give it more time and a higher dose before drawing any conclusions. Our page on how long Mounjaro takes to work covers the week-by-week picture in more detail.

Could something be blunting the medicine's effect?

Tirzepatide slows gastric emptying and increases satiety signals, but it doesn't remove the need for a calorie deficit entirely. If appetite suppression is working but food choices or portion sizes haven't shifted much, weight loss can stall even when the medicine is doing its job at the receptor level. This isn't a character flaw; it's biology. The medicine lowers the ceiling on hunger, but some people find their eating patterns are driven by habit or mood more than hunger, and those patterns need different tools alongside the prescription.

A few other factors can quietly reduce how well the medicine works. Sleep deprivation raises hunger hormones independently of GLP-1 activity. Significant stress does the same. Certain other medicines (steroids and some antidepressants, for instance) can counteract weight-loss effects. None of this means Mounjaro has failed; it means the picture is more complicated than a single variable. A prescriber who understands your full health history is better placed than any algorithm to untangle it. If you've been asking yourself why Mounjaro isn't working for you specifically, that personal-factors lens is usually where the answer sits.

One practical note on timing: people who restart after a gap (say, a holiday where the pen wasn't kept refrigerated properly, or a week where a dose was missed) sometimes find their response temporarily weaker. The medicine builds a steady-state effect with consistent weekly dosing, and interruptions matter more than many people realise.

What does a real plateau look like, and when should you act?

Weight loss is rarely linear. A period of four to six weeks without scale movement doesn't automatically mean Mounjaro has stopped working; it may mean your body is recomposing (losing fat while fluid or muscle mass shifts), or that you're in a natural biological pause. These plateaus are documented in trial data and are not unique to any particular medicine.

A genuine non-response is different. According to NICE's appraisal of tirzepatide (TA1026), if someone has not lost at least 5% of their body weight after six months on the highest tolerated dose, the clinical value of continuing should be reassessed. That's a clinical decision, not a self-help one. Your prescriber may consider whether the dose can be increased further, whether there are modifiable factors, or whether a different treatment pathway makes more sense.

The steps to take if Mounjaro isn't working are best worked through with clinical support rather than alone. Switching doses, stopping abruptly, or supplementing with other products without prescriber input carries its own risks. If you're concerned about your progress, reaching out to whoever prescribes your treatment (ideally with a few weeks of weight data) is the right first step. Our aftercare team is available seven days a week for patients with questions between reviews.

Is switching to a higher dose or different treatment the answer?

Sometimes. Titration to a higher maintenance dose is the most straightforward response to slow initial progress, provided it's clinically appropriate and you're tolerating the current dose reasonably well. The data from SURMOUNT-1 are clear that weight loss outcomes improve substantially at higher doses, the gap between 5 mg and 15 mg results is significant.

For some people, a broader review is warranted. Our weight-loss treatment overview outlines the options licensed in the UK and how they compare. The Mounjaro treatment page covers the licensed schedule and eligibility criteria in full. If the question is whether Mounjaro is the right medicine for you at all, or whether the dose you're on is optimal, that's precisely what a clinical consultation is for, not something to resolve by reading forums or stopping treatment unilaterally.

Cost and access questions sometimes come up here too. If affordability is making it hard to stay consistent with treatment, our page on the Mounjaro UK price increase gives honest context about what's driven market prices and what to realistically expect. Consistency matters more than almost any other variable: irregular dosing is one of the most underappreciated reasons why results fall short of trial data.

If you'd like a clinician to look at your situation properly (your dose, your history, your concerns) starting a free consultation with our prescribers is the most useful next step we can offer.